Compared with conventional medications such as angiotensin-converting enzyme (Regev et al., 2022) inhibitors and angiotensin receptor blockers (ARBs), HKC demonstrates distinct advantages in treating chronic kidney disease (CKD), as it improves renal function and reduces proteinuria without adverse effects on blood pressure. The gene discussed is ACE; the disease is chronic kidney disease.